메뉴 건너뛰기




Volumn 14, Issue 11, 2017, Pages

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

(23)  Mayer, Kenneth H a   Seaton, Kelly E b   Huang, Yunda c   Grunenberg, Nicole c   Isaacs, Abby c   Allen, Mary d   Ledgerwood, Julie E d   Frank, Ian e   Sobieszczyk, Magdalena E f   Baden, Lindsey R g   Rodriguez, Benigno h   Van Tieu, Hong i   Tomaras, Georgia D b   Deal, Aaron b   Goodman, Derrick b   Bailer, Robert T d   Ferrari, Guido b   Jensen, Ryan c   Hural, John c   Graham, Barney S d   more..


Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DRUG ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG; VRC 01; VRC01 MONOCLONAL ANTIBODY;

EID: 85036569550     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1002435     Document Type: Article
Times cited : (101)

References (66)
  • 1
    • 85036590184 scopus 로고    scopus 로고
    • UNAIDS DATA 2017, published 20 July 2017
    • UNAIDS DATA 2017, published 20 July 2017. http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf
  • 2
  • 3
    • 85036594955 scopus 로고    scopus 로고
    • UNAIDS. Prevention gap report 2016 [January 14, 201
    • UNAIDS. Prevention gap report 2016 [January 14, 2017]. http://www.unaids.org/en/resources/campaigns/prevention-gap.
  • 4
    • 84948845152 scopus 로고    scopus 로고
    • Ending the HIV-AIDS Pandemic—Follow the Science
    • 2662455
    • Fauci AS, Marston HD, Ending the HIV-AIDS Pandemic—Follow the Science. N Engl J Med. 2015;373(23):2197–9. doi: 10.1056/NEJMp1502020 26624554.
    • (2015) N Engl J Med , vol.373 , Issue.23 , pp. 2197-2199
    • Fauci, A.S.1    Marston, H.D.2
  • 5
    • 84907993259 scopus 로고    scopus 로고
    • Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies
    • 2514259
    • Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J Virol. 2014;88(21):12623–43. doi: 10.1128/JVI.01705-14 25142591
    • (2014) J Virol , vol.88 , Issue.21 , pp. 12623-12643
    • Hraber, P.1    Korber, B.T.2    Lapedes, A.S.3    Bailer, R.T.4    Seaman, M.S.5    Gao, H.6
  • 6
    • 77952311370 scopus 로고    scopus 로고
    • The role of antibodies in HIV vaccines
    • 2019281
    • Mascola JR, Montefiori DC, The role of antibodies in HIV vaccines. Annu Rev Immunol. 2010;28:413–44. doi: 10.1146/annurev-immunol-030409-101256 20192810.
    • (2010) Annu Rev Immunol , vol.28 , pp. 413-444
    • Mascola, J.R.1    Montefiori, D.C.2
  • 7
    • 84982958690 scopus 로고    scopus 로고
    • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
    • 2743431
    • Rademeyer C, Korber B, Seaman MS, Giorgi EE, Thebus R, Robles A, et al. Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog. 2016;12(7):e1005742. doi: 10.1371/journal.ppat.1005742 27434311
    • (2016) PLoS Pathog , vol.12 , Issue.7 , pp. e1005742
    • Rademeyer, C.1    Korber, B.2    Seaman, M.S.3    Giorgi, E.E.4    Thebus, R.5    Robles, A.6
  • 8
    • 84959517396 scopus 로고    scopus 로고
    • HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies
    • 2686920
    • de Taeye SW, Moore JP, Sanders RW, HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. Trends Immunol. 2016;37(3):221–32. doi: 10.1016/j.it.2016.01.007 26869204.
    • (2016) Trends Immunol , vol.37 , Issue.3 , pp. 221-232
    • de Taeye, S.W.1    Moore, J.P.2    Sanders, R.W.3
  • 9
    • 84860759632 scopus 로고    scopus 로고
    • B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study
    • 2256597
    • Haynes BF, Kelsoe G, Harrison SC, Kepler TB, B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol. 2012;30(5):423–33. doi: 10.1038/nbt.2197 22565972
    • (2012) Nat Biotechnol , vol.30 , Issue.5 , pp. 423-433
    • Haynes, B.F.1    Kelsoe, G.2    Harrison, S.C.3    Kepler, T.B.4
  • 10
    • 84877609579 scopus 로고    scopus 로고
    • Rational HIV immunogen design to target specific germline B cell receptors
    • 2353918
    • Jardine J, Julien JP, Menis S, Ota T, Kalyuzhniy O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133):711–6. doi: 10.1126/science.1234150 23539181
    • (2013) Science , vol.340 , Issue.6133 , pp. 711-716
    • Jardine, J.1    Julien, J.P.2    Menis, S.3    Ota, T.4    Kalyuzhniy, O.5    McGuire, A.6
  • 11
    • 84937511644 scopus 로고    scopus 로고
    • HIV. The modern era of HIV-1 vaccine development
    • 2616093
    • Mascola JR, HIV. The modern era of HIV-1 vaccine development. Science. 2015;349(6244):139–40. doi: 10.1126/science.aac7800 26160931.
    • (2015) Science , vol.349 , Issue.6244 , pp. 139-140
    • Mascola, J.R.1
  • 12
    • 84878626061 scopus 로고    scopus 로고
    • Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies
    • 2353012
    • McGuire AT, Hoot S, Dreyer AM, Lippy A, Stuart A, Cohen KW, et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J Exp Med. 2013;210(4):655–63. doi: 10.1084/jem.20122824 23530120
    • (2013) J Exp Med , vol.210 , Issue.4 , pp. 655-663
    • McGuire, A.T.1    Hoot, S.2    Dreyer, A.M.3    Lippy, A.4    Stuart, A.5    Cohen, K.W.6
  • 13
    • 84969835812 scopus 로고    scopus 로고
    • Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design
    • 2716824
    • Burton DR, Hangartner L, Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. Annu Rev Immunol. 2016;34:635–59. doi: 10.1146/annurev-immunol-041015-055515 27168247.
    • (2016) Annu Rev Immunol , vol.34 , pp. 635-659
    • Burton, D.R.1    Hangartner, L.2
  • 14
    • 84883796903 scopus 로고    scopus 로고
    • Antibodies in HIV-1 vaccine development and therapy
    • 2403101
    • Klein F, Mouquet H, Dosenovic P, Scheid JF, Scharf L, Nussenzweig MC, Antibodies in HIV-1 vaccine development and therapy. Science. 2013;341(6151):1199–204. doi: 10.1126/science.1241144 24031012
    • (2013) Science , vol.341 , Issue.6151 , pp. 1199-1204
    • Klein, F.1    Mouquet, H.2    Dosenovic, P.3    Scheid, J.F.4    Scharf, L.5    Nussenzweig, M.C.6
  • 15
    • 84879302728 scopus 로고    scopus 로고
    • HIV-1 neutralizing antibodies: understanding nature's pathways
    • 2377262
    • Mascola JR, Haynes BF, HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev. 2013;254(1):225–44. doi: 10.1111/imr.12075 23772623
    • (2013) Immunol Rev , vol.254 , Issue.1 , pp. 225-244
    • Mascola, J.R.1    Haynes, B.F.2
  • 16
    • 84999836139 scopus 로고    scopus 로고
    • Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth
    • 2785191
    • Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 2016;45(5):1108–21. doi: 10.1016/j.immuni.2016.10.027 27851912.
    • (2016) Immunity , vol.45 , Issue.5 , pp. 1108-1121
    • Huang, J.1    Kang, B.H.2    Ishida, E.3    Zhou, T.4    Griesman, T.5    Sheng, Z.6
  • 17
    • 80052287270 scopus 로고    scopus 로고
    • Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01
    • 2171549
    • Li Y, O'Dell S, Walker LM, Wu X, Guenaga J, Feng Y, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85(17):8954–67. doi: 10.1128/JVI.00754-11 21715490
    • (2011) J Virol , vol.85 , Issue.17 , pp. 8954-8967
    • Li, Y.1    O'Dell, S.2    Walker, L.M.3    Wu, X.4    Guenaga, J.5    Feng, Y.6
  • 18
    • 77954920017 scopus 로고    scopus 로고
    • Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    • 2061623
    • Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856–61. doi: 10.1126/science.1187659 20616233
    • (2010) Science , vol.329 , Issue.5993 , pp. 856-861
    • Wu, X.1    Yang, Z.Y.2    Li, Y.3    Hogerkorp, C.M.4    Schief, W.R.5    Seaman, M.S.6
  • 19
    • 77954943648 scopus 로고    scopus 로고
    • Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01
    • 2061623
    • Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science. 2010;329(5993):811–7. doi: 10.1126/science.1192819 20616231
    • (2010) Science , vol.329 , Issue.5993 , pp. 811-817
    • Zhou, T.1    Georgiev, I.2    Wu, X.3    Yang, Z.Y.4    Dai, K.5    Finzi, A.6
  • 20
    • 84937761089 scopus 로고    scopus 로고
    • Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection
    • 2586548
    • Wu X, Zhang Z, Schramm CA, Joyce MG, Kwon YD, Zhou T, et al. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell. 2015;161(3):470–85. doi: 10.1016/j.cell.2015.03.004 25865483
    • (2015) Cell , vol.161 , Issue.3 , pp. 470-485
    • Wu, X.1    Zhang, Z.2    Schramm, C.A.3    Joyce, M.G.4    Kwon, Y.D.5    Zhou, T.6
  • 21
    • 84907983318 scopus 로고    scopus 로고
    • Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
    • 2511903
    • Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature. 2014;514(7524):642–5. doi: 10.1038/nature13612 25119033
    • (2014) Nature , vol.514 , Issue.7524 , pp. 642-645
    • Ko, S.Y.1    Pegu, A.2    Rudicell, R.S.3    Yang, Z.Y.4    Joyce, M.G.5    Chen, X.6
  • 22
    • 84904497424 scopus 로고    scopus 로고
    • Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
    • 2499088
    • Pegu A, Yang ZY, Boyington JC, Wu L, Ko SY, Schmidt SD, et al. Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med. 2014;6(243):243ra88. doi: 10.1126/scitranslmed.3008992 24990883
    • (2014) Sci Transl Med , vol.6 , Issue.243 , pp. 243ra88
    • Pegu, A.1    Yang, Z.Y.2    Boyington, J.C.3    Wu, L.4    Ko, S.Y.5    Schmidt, S.D.6
  • 23
    • 84907971356 scopus 로고    scopus 로고
    • Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo
    • 2514260
    • Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J Virol. 2014;88(21):12669–82. doi: 10.1128/JVI.02213-14 25142607
    • (2014) J Virol , vol.88 , Issue.21 , pp. 12669-12682
    • Rudicell, R.S.1    Kwon, Y.D.2    Ko, S.Y.3    Pegu, A.4    Louder, M.K.5    Georgiev, I.S.6
  • 24
    • 84929613728 scopus 로고    scopus 로고
    • Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
    • 2578728
    • Saunders KO, Pegu A, Georgiev IS, Zeng M, Joyce MG, Yang ZY, et al. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol. 2015;89(11):5895–903. doi: 10.1128/JVI.00210-15 25787288
    • (2015) J Virol , vol.89 , Issue.11 , pp. 5895-5903
    • Saunders, K.O.1    Pegu, A.2    Georgiev, I.S.3    Zeng, M.4    Joyce, M.G.5    Yang, Z.Y.6
  • 25
    • 80052925616 scopus 로고    scopus 로고
    • Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    • 2176475
    • Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–7. doi: 10.1126/science.1207227 21764753
    • (2011) Science , vol.333 , Issue.6049 , pp. 1633-1637
    • Scheid, J.F.1    Mouquet, H.2    Ueberheide, B.3    Diskin, R.4    Klein, F.5    Oliveira, T.Y.6
  • 26
    • 84864363185 scopus 로고    scopus 로고
    • Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120
    • 2274517
    • West AP, Jr.Diskin R, Nussenzweig MC, Bjorkman PJ, Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A. 2012;109(30):E2083–90. doi: 10.1073/pnas.1208984109 22745174
    • (2012) Proc Natl Acad Sci U S A , vol.109 , Issue.30 , pp. E2083-E2090
    • West, A.P.1    Diskin, R.2    Nussenzweig, M.C.3    Bjorkman, P.J.4
  • 27
    • 80052942203 scopus 로고    scopus 로고
    • Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    • 2183598
    • Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science. 2011;333(6049):1593–602. doi: 10.1126/science.1207532 21835983
    • (2011) Science , vol.333 , Issue.6049 , pp. 1593-1602
    • Wu, X.1    Zhou, T.2    Zhu, J.3    Zhang, B.4    Georgiev, I.5    Wang, C.6
  • 28
    • 84882589754 scopus 로고    scopus 로고
    • Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies
    • 2391165
    • Zhou T, Zhu J, Wu X, Moquin S, Zhang B, Acharya P, et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity. 2013;39(2):245–58. doi: 10.1016/j.immuni.2013.04.012 23911655
    • (2013) Immunity , vol.39 , Issue.2 , pp. 245-258
    • Zhou, T.1    Zhu, J.2    Wu, X.3    Moquin, S.4    Zhang, B.5    Acharya, P.6
  • 29
    • 0034971499 scopus 로고    scopus 로고
    • Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group
    • 1141950
    • Groothuis JR, Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Northern Hemisphere Expanded Access Study Group. Pediatr Infect Dis J. 2001;20(6):628–30. 11419509.
    • (2001) Pediatr Infect Dis J , vol.20 , Issue.6 , pp. 628-630
    • Groothuis, J.R.1
  • 30
    • 74849098405 scopus 로고    scopus 로고
    • Treatment with monoclonal antibodies against Clostridium difficile toxins
    • 2008997
    • Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197–205. doi: 10.1056/NEJMoa0907635 20089970.
    • (2010) N Engl J Med , vol.362 , Issue.3 , pp. 197-205
    • Lowy, I.1    Molrine, D.C.2    Leav, B.A.3    Blair, B.M.4    Baxter, R.5    Gerding, D.N.6
  • 31
    • 84875695802 scopus 로고    scopus 로고
    • Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study
    • 2335638
    • Chung RT, Gordon FD, Curry MP, Schiano TD, Emre S, Corey K, et al. Human monoclonal antibody MBL-HCV1 delays HCV viral rebound following liver transplantation: a randomized controlled study. Am J Transplant. 2013;13(4):1047–54. doi: 10.1111/ajt.12083 23356386
    • (2013) Am J Transplant , vol.13 , Issue.4 , pp. 1047-1054
    • Chung, R.T.1    Gordon, F.D.2    Curry, M.P.3    Schiano, T.D.4    Emre, S.5    Corey, K.6
  • 33
    • 84946480939 scopus 로고    scopus 로고
    • Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults
    • 2633260
    • Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol. 2015;182(3):289–301. doi: 10.1111/cei.12692 26332605
    • (2015) Clin Exp Immunol , vol.182 , Issue.3 , pp. 289-301
    • Ledgerwood, J.E.1    Coates, E.E.2    Yamshchikov, G.3    Saunders, J.G.4    Holman, L.5    Enama, M.E.6
  • 34
    • 84954445565 scopus 로고    scopus 로고
    • Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
    • 2670209
    • Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci Transl Med. 2015;7(319):319ra206. doi: 10.1126/scitranslmed.aad5752 26702094.
    • (2015) Sci Transl Med , vol.7 , Issue.319 , pp. 319ra206
    • Lynch, R.M.1    Boritz, E.2    Coates, E.E.3    DeZure, A.4    Madden, P.5    Costner, P.6
  • 35
    • 85019570515 scopus 로고    scopus 로고
    • Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults
    • 2836874
    • Huang Y, Zhang L, Ledgerwood J, Grunenberg N, Bailer R, Isaacs A, et al. Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults. MAbs. 2017:1–9. doi: 10.1080/19420862.2017.1311435 28368743.
    • MAbs , vol.2017 , pp. 1-9
    • Huang, Y.1    Zhang, L.2    Ledgerwood, J.3    Grunenberg, N.4    Bailer, R.5    Isaacs, A.6
  • 36
    • 85036538909 scopus 로고    scopus 로고
    • Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events
    • U.S. Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0. [Updated August 2009]. 2004.
    • (2004) Version , pp. 1
  • 37
    • 60349089294 scopus 로고    scopus 로고
    • Measuring HIV neutralization in a luciferase reporter gene assay
    • 1902083
    • Montefiori DC, Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485:395–405. doi: 10.1007/978-1-59745-170-3_26 19020839.
    • (2009) Methods Mol Biol , vol.485 , pp. 395-405
    • Montefiori, D.C.1
  • 38
    • 84906084946 scopus 로고    scopus 로고
    • Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
    • 2429134
    • Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin CL, Bilska M, Greene KM, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409:131–46. doi: 10.1016/j.jim.2013.11.022 24291345
    • (2014) J Immunol Methods , vol.409 , pp. 131-146
    • Sarzotti-Kelsoe, M.1    Bailer, R.T.2    Turk, E.3    Lin, C.L.4    Bilska, M.5    Greene, K.M.6
  • 39
    • 84896739535 scopus 로고    scopus 로고
    • Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies
    • 2435244
    • deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2014;88(5):2489–507. doi: 10.1128/JVI.02853-13 24352443
    • (2014) J Virol , vol.88 , Issue.5 , pp. 2489-2507
    • deCamp, A.1    Hraber, P.2    Bailer, R.T.3    Seaman, M.S.4    Ochsenbauer, C.5    Kappes, J.6
  • 40
    • 79960342938 scopus 로고    scopus 로고
    • An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum
    • 2154348
    • Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol. 2011;85(14):7029–36. doi: 10.1128/JVI.00171-11 21543485
    • (2011) J Virol , vol.85 , Issue.14 , pp. 7029-7036
    • Ferrari, G.1    Pollara, J.2    Kozink, D.3    Harms, T.4    Drinker, M.5    Freel, S.6
  • 41
    • 84904113226 scopus 로고    scopus 로고
    • HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities
    • 2480772
    • Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, et al. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol. 2014;88(14):7715–26. doi: 10.1128/JVI.00156-14 24807721
    • (2014) J Virol , vol.88 , Issue.14 , pp. 7715-7726
    • Pollara, J.1    Bonsignori, M.2    Moody, M.A.3    Liu, P.4    Alam, S.M.5    Hwang, K.K.6
  • 42
    • 79952310878 scopus 로고    scopus 로고
    • A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples
    • 2119294
    • Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J Immunol Methods. 2011;366(1–2):8–19. doi: 10.1016/j.jim.2010.12.016 21192942
    • (2011) J Immunol Methods , vol.366 , Issue.1-2 , pp. 8-19
    • Ackerman, M.E.1    Moldt, B.2    Wyatt, R.T.3    Dugast, A.S.4    McAndrew, E.5    Tsoukas, S.6
  • 43
    • 84984793166 scopus 로고    scopus 로고
    • Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses
    • 2757971
    • Tay MZ, Liu P, Williams LD, McRaven MD, Sawant S, Gurley TC, et al. Antibody-Mediated Internalization of Infectious HIV-1 Virions Differs among Antibody Isotypes and Subclasses. PLoS Pathog. 2016;12(8):e1005817. doi: 10.1371/journal.ppat.1005817 27579713
    • (2016) PLoS Pathog , vol.12 , Issue.8 , pp. e1005817
    • Tay, M.Z.1    Liu, P.2    Williams, L.D.3    McRaven, M.D.4    Sawant, S.5    Gurley, T.C.6
  • 44
    • 33746689169 scopus 로고    scopus 로고
    • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    • 1703960
    • Liao HX, Sutherland LL, Xia SM, Brock ME, Scearce RM, Vanleeuwen S, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology. 2006;353(2):268–82. doi: 10.1016/j.virol.2006.04.043 17039602
    • (2006) Virology , vol.353 , Issue.2 , pp. 268-282
    • Liao, H.X.1    Sutherland, L.L.2    Xia, S.M.3    Brock, M.E.4    Scearce, R.M.5    Vanleeuwen, S.6
  • 45
    • 9044241681 scopus 로고    scopus 로고
    • Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
    • 855156
    • Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70(2):1100–8. 8551569
    • (1996) J Virol , vol.70 , Issue.2 , pp. 1100-1108
    • Trkola, A.1    Purtscher, M.2    Muster, T.3    Ballaun, C.4    Buchacher, A.5    Sullivan, N.6
  • 46
    • 16944363559 scopus 로고    scopus 로고
    • Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
    • 935972
    • Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997;176(5):1215–24. 9359721.
    • (1997) J Infect Dis , vol.176 , Issue.5 , pp. 1215-1224
    • Johnson, S.1    Oliver, C.2    Prince, G.A.3    Hemming, V.G.4    Pfarr, D.S.5    Wang, S.C.6
  • 47
    • 80052184942 scopus 로고    scopus 로고
    • Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin
    • 2182512
    • Whittle JR, Zhang R, Khurana S, King LR, Manischewitz J, Golding H, et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A. 2011;108(34):14216–21. doi: 10.1073/pnas.1111497108 21825125
    • (2011) Proc Natl Acad Sci U S A , vol.108 , Issue.34 , pp. 14216-14221
    • Whittle, J.R.1    Zhang, R.2    Khurana, S.3    King, L.R.4    Manischewitz, J.5    Golding, H.6
  • 48
    • 84897521911 scopus 로고    scopus 로고
    • Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity
    • 2455465
    • Liu P, Williams LD, Shen X, Bonsignori M, Vandergrift NA, Overman RG, et al. Capacity for infectious HIV-1 virion capture differs by envelope antibody specificity. J Virol. 2014;88(9):5165–70. doi: 10.1128/JVI.03765-13 24554654
    • (2014) J Virol , vol.88 , Issue.9 , pp. 5165-5170
    • Liu, P.1    Williams, L.D.2    Shen, X.3    Bonsignori, M.4    Vandergrift, N.A.5    Overman, R.G.6
  • 49
    • 84880310997 scopus 로고    scopus 로고
    • Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
    • 2365844
    • Liu P, Yates NL, Shen X, Bonsignori M, Moody MA, Liao HX, et al. Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol. 2013;87(14):7828–36. doi: 10.1128/JVI.02737-12 23658446
    • (2013) J Virol , vol.87 , Issue.14 , pp. 7828-7836
    • Liu, P.1    Yates, N.L.2    Shen, X.3    Bonsignori, M.4    Moody, M.A.5    Liao, H.X.6
  • 51
    • 84962419508 scopus 로고    scopus 로고
    • Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection
    • 2702893
    • Wagh K, Bhattacharya T, Williamson C, Robles A, Bayne M, Garrity J, et al. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS Pathog. 2016;12(3):e1005520. doi: 10.1371/journal.ppat.1005520 27028935
    • (2016) PLoS Pathog , vol.12 , Issue.3 , pp. e1005520
    • Wagh, K.1    Bhattacharya, T.2    Williamson, C.3    Robles, A.4    Bayne, M.5    Garrity, J.6
  • 52
    • 0026557112 scopus 로고
    • Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
    • 174105
    • Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature. 1992;355(6362):728–30. doi: 10.1038/355728a0 1741059.
    • (1992) Nature , vol.355 , Issue.6362 , pp. 728-730
    • Emini, E.A.1    Schleif, W.A.2    Nunberg, J.H.3    Conley, A.J.4    Eda, Y.5    Tokiyoshi, S.6
  • 53
    • 2942534479 scopus 로고    scopus 로고
    • Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    • 1518156
    • Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis. 2004;189(12):2167–73. doi: 10.1086/420833 15181562.
    • (2004) J Infect Dis , vol.189 , Issue.12 , pp. 2167-2173
    • Ferrantelli, F.1    Rasmussen, R.A.2    Buckley, K.A.3    Li, P.L.4    Wang, T.5    Montefiori, D.C.6
  • 54
    • 68349160853 scopus 로고    scopus 로고
    • Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
    • 1952596
    • Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15(8):951–4. doi: 10.1038/nm.1974 19525965
    • (2009) Nat Med , vol.15 , Issue.8 , pp. 951-954
    • Hessell, A.J.1    Poignard, P.2    Hunter, M.3    Hangartner, L.4    Tehrani, D.M.5    Bleeker, W.K.6
  • 55
    • 0032947286 scopus 로고    scopus 로고
    • Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    • 1019629
    • Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73(5):4009–18. 10196297
    • (1999) J Virol , vol.73 , Issue.5 , pp. 4009-4018
    • Mascola, J.R.1    Lewis, M.G.2    Stiegler, G.3    Harris, D.4    VanCott, T.C.5    Hayes, D.6
  • 56
    • 0030823325 scopus 로고    scopus 로고
    • Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
    • 931179
    • Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12. J Virol. 1997;71(10):7198–206. 9311792
    • (1997) J Virol , vol.71 , Issue.10 , pp. 7198-7206
    • Mascola, J.R.1    Louder, M.K.2    VanCott, T.C.3    Sapan, C.V.4    Lambert, J.S.5    Muenz, L.R.6
  • 57
    • 0033951746 scopus 로고    scopus 로고
    • Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
    • 1065511
    • Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, Hanson CE, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207–10. doi: 10.1038/72318 10655111.
    • (2000) Nat Med , vol.6 , Issue.2 , pp. 207-210
    • Mascola, J.R.1    Stiegler, G.2    VanCott, T.C.3    Katinger, H.4    Carpenter, C.B.5    Hanson, C.E.6
  • 58
    • 0034864776 scopus 로고    scopus 로고
    • Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro
    • 1148377
    • Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75(17):8340–7. doi: 10.1128/JVI.75.17.8340-8347.2001 11483779
    • (2001) J Virol , vol.75 , Issue.17 , pp. 8340-8347
    • Parren, P.W.1    Marx, P.A.2    Hessell, A.J.3    Luckay, A.4    Harouse, J.5    Cheng-Mayer, C.6
  • 59
    • 0032907674 scopus 로고    scopus 로고
    • Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys
    • 993086
    • Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, Ross W, et al. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat Med. 1999;5(2):204–10. doi: 10.1038/5568 9930869.
    • (1999) Nat Med , vol.5 , Issue.2 , pp. 204-210
    • Shibata, R.1    Igarashi, T.2    Haigwood, N.3    Buckler-White, A.4    Ogert, R.5    Ross, W.6
  • 61
    • 84900389177 scopus 로고    scopus 로고
    • HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission
    • 2471436
    • Voronin Y, Mofenson LM, Cunningham CK, Fowler MG, Kaleebu P, McFarland EJ, et al. HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med. 2014;11(4):e1001616. doi: 10.1371/journal.pmed.1001616 24714363
    • (2014) PLoS Med , vol.11 , Issue.4 , pp. e1001616
    • Voronin, Y.1    Mofenson, L.M.2    Cunningham, C.K.3    Fowler, M.G.4    Kaleebu, P.5    McFarland, E.J.6
  • 62
    • 84908077691 scopus 로고    scopus 로고
    • Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity
    • 2521548
    • Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV, Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243–53. doi: 10.1016/j.cell.2014.08.023 25215485
    • (2014) Cell , vol.158 , Issue.6 , pp. 1243-1253
    • Bournazos, S.1    Klein, F.2    Pietzsch, J.3    Seaman, M.S.4    Nussenzweig, M.C.5    Ravetch, J.V.6
  • 63
    • 84966389751 scopus 로고    scopus 로고
    • A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
    • 2712015
    • Gautam R, Nishimura Y, Pegu A, Nason MC, Klein F, Gazumyan A, et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature. 2016;533(7601):105–9. doi: 10.1038/nature17677 27120156
    • (2016) Nature , vol.533 , Issue.7601 , pp. 105-109
    • Gautam, R.1    Nishimura, Y.2    Pegu, A.3    Nason, M.C.4    Klein, F.5    Gazumyan, A.6
  • 64
    • 84922982202 scopus 로고    scopus 로고
    • Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes
    • 2552050
    • Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J Virol. 2015;89(5):2659–71. doi: 10.1128/JVI.03136-14 25520506
    • (2015) J Virol , vol.89 , Issue.5 , pp. 2659-2671
    • Kong, R.1    Louder, M.K.2    Wagh, K.3    Bailer, R.T.4    deCamp, A.5    Greene, K.6
  • 65
    • 84975270914 scopus 로고    scopus 로고
    • Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency
    • 2731547
    • Bournazos S, Gazumyan A, Seaman MS, Nussenzweig MC, Ravetch JV, Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell. 2016;165(7):1609–20. doi: 10.1016/j.cell.2016.04.050 27315478
    • (2016) Cell , vol.165 , Issue.7 , pp. 1609-1620
    • Bournazos, S.1    Gazumyan, A.2    Seaman, M.S.3    Nussenzweig, M.C.4    Ravetch, J.V.5
  • 66
    • 84975221851 scopus 로고    scopus 로고
    • Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity
    • 2731547
    • Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell. 2016;165(7):1621–31. doi: 10.1016/j.cell.2016.05.024 27315479
    • (2016) Cell , vol.165 , Issue.7 , pp. 1621-1631
    • Huang, Y.1    Yu, J.2    Lanzi, A.3    Yao, X.4    Andrews, C.D.5    Tsai, L.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.